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and 0.2 ml of saline). The following substances were administered 
intragastrically 2 times a day at 7-hour intervals for 30 days start-
ing from the 1st day of EAE induction: anti-S100 (n = 20, 2.5 mL/
kg/d); distilled water (control; n = 20, 5 mL/kg/d). Reference drug 
(Glatiramer acetate, Copaxone®, Teva, Israel, n = 20) was adminis-
tered intramuscularly (4 mg/kg) from the 2nd to the 25th day after 
EAE induction.
Results: The severity of neurologic symptoms was assessed in points: 
muscle weakness, tremor (0.5 point); resistant paresis (1 point); 
paralysis (1.5 points). Clinical Index (CI) was calculated as a sum of 
the symptoms for 4 limbs. CI was defined as zero if visible clinical 
signs were absent, and as 6 in case of animal’s death. Cumulative 
index for each rat was calculated as a sum of individual CI for the 
total disease period (30 days). Time to disease onset (days) and the 
mean severity of the disease (points) were recorded in each group.
The key results of the study are presented in the Table.
Conclusion: Anti-S100 ameliorated clinical symptoms of EAE in 
Wistar rats: they both significantly reduced the severity of the disease 
and delayed the disease onset. The results give promise to patients in 
a search of a treatment option for multiple sclerosis.
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Introduction: In Sweden, some triptans became available over the 
counter (OTC) in 2008. The present study describes the utilization 
pattern of prescribed and OTC triptans in Sweden over time.
Patients (or Materials) and Methods: Wholesaler and aggregated 
sales data from the National Corporation of Swedish Pharmacies 
between 1991 and 2006, and patient identity data on dispensed pre-
scriptions between 2006 and 2010 from the National Prescribed 
Drug Register were used to investigate volume and expenditure of 
triptans over time. Prevalence was calculated for 2007 and 2011, 
measured as the number of patients/1000 inhabitants dispensed at 
least 1 triptan prescription. To illustrate proportions of patients dis-
pensed large and small amounts of the drug, respectively, Lorentz 
percentiles and Lorentz curves were used. Analyses were done by 
age and gender.
Results: Volumes of triptans sold has increased continuously to 
7.0 million defined daily doses (DDD) dispensed on prescriptions 
and 0.7 million DDDs OTCin 2011. The prevalence of triptan uti-
lization was 10.0 in 2007 and increased slightly to 10.1 in 2011. 
A marked gender difference was found with a 3.6 times higher 
prevalence of triptan use in women both years. The mean number of 
DDD increased with 10%, from 67 DDD per patient in 2007 to 74 
DDD per patient in 2011. The median volume per patient increased 
even more, 20%, from 30 DDD per patient in 2007 to 36 DDD 
per patient in 2011. Dispensed triptans were unevenly distributed 
within the population. In 2007, in women, 46% of the volume 
was purchased by 10% of those consuming the largest amounts. 
In men, the corresponding proportion consumed by 10% heavy 
users was 50%.
Conclusion: Triptans OTC has increased since the introduction as 
has the purchases of prescribed triptans. The number of patients 
dispensed triptans on prescription remained stable during the period 
studied even though the volumes increased.
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Introduction: There could be an opportunity for health authorities 
to take advantage of oral generic atypical antipsychotic drugs (AAPs) 
given their considerable expenditure across countries. However, 
schizophrenia and bipolar disorders (BPD) are complex to treat, 
with the need to tailor treatments. Consequently, there is a need to 
assess changes in risperidone utilization before and after oral generic 
risperidone was reimbursed among European countries, as well as 
the utilization of generic versus originator risperidone, to provide 
future guidance.
Patients (or Materials) and Methods: We principally used an inter-
rupted time series design of monthly aggregated AAP utilization 
(2011 DDDs) up to 2 years before generic risperidone became avail-
able and reimbursed and up to 6 years after in Austria, Belgium, 
Ireland (GMS population), Scotland, Spain (Catalonia), and 
Sweden; (ii) Demand-side measures captured and categorised using 
the 4Es (Education, Engineering, Economics and Enforcement). 
Expenditure was also measured. Only administrative databases 
were used.
Results: There were generally no specific measures among the vari-
ous authorities to preferentially encourage the prescribing of oral 
Groups, 
the number 
of animals
Proportion 
of Animals 
With Symp-
toms
Severity of 
Symptoms
Time to Dis-
ease Onset, 
days
Mean 
Cumulative 
CI, Points 
(M ± m)
Mild, % Average, % Severe %
Control,  
n = 20
80 20 25 35 9.5 (8.0–
11.3)
27.53 ± 
7.19
Glatiramer 
acetate,  
n = 20
65 5 40 20 10.0 (9.0–
11.0)
18.03 ± 
6.20
Anti-S100, 
n = 20
85 40 40 5* 12.0 (8.0–
14.0)
18.96 ± 
5.94
⁎The difference with control is significant at P < 0.05 (chi-square test).
